The Renton, Wash.-based system’s decision mirrors those recently made by Cleveland Clinic and New York City-based Mount Sinai.
Providence decided not to administer Aduhelm at this time because of the ongoing investigation of the drug’s approval, as well as its risks and the lack of clear evidence demonstrating clinical benefit, a spokesperson told Becker’s July 16.
“We understand that people living with Alzheimer’s and their families are seeking disease-modifying treatments, and we are hopeful that with more research, we will soon be able to offer such a treatment to improve the lives of our patients and families,” Providence said.
Providence said it will reevaluate Aduhelm’s potential use for its patients when the investigation is complete and more data on the drug’s clinical benefit becomes available.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.